In Europe, a shift by public hospitals toward greater use of LB in NSCLC—where tissue biopsy still predominates—is conditioned by regional policies [85], with some moves toward paying for EGFR mutation testing (in Italy, Slovenia, and the UK, for instance), but with widespread hesitation over other biomarkers. Here, EGFR is linked to non-small cell lung carcinoma.